Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common stock issued for cash at $5.90 per share	Amgen	Preferred Stock	Common Stock	Common Stock Common stock issued for cash at $5.90 per share	Common Stock Amgen	Additional Paid-In Capital	Additional Paid-In Capital Common stock issued for cash at $5.90 per share	Additional Paid-In Capital Amgen	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2015	$ 109,621,634			$ 16	$ 151,914			$ 426,873,358			$ (136,425)	$ (316,712,041)	$ (555,188)
Beginning Balance, Shares at Sep. 30, 2015				15,652	59,544,677
Exercise of warrants, Amount	3,691,398				$ 853			3,690,545
Exercise of warrants, Shares					852,532
Exercise of stock options, Amount	133,869				$ 37			133,832
Exercise of stock options, Shares					37,187
Stock-based compensation	11,595,816							11,595,816
Common stock- Restricted Stock Units vesting, Amount	(670,765)				$ 428			(671,193)
Common stock- Restricted Stock Units vesting, Shares					428,187
Stock issuances		$ 43,231,435	$ 9,000,000			$ 7,627	$ 1,257		$ 43,223,808	$ 8,998,743
Stock issuances, Shares						7,627,119	1,256,983
Foreign currency translation adjustments	143,874										143,874
Net loss	(81,723,002)											(81,723,002)
Ending Balance, Amount at Sep. 30, 2016	95,024,259			$ 16	$ 162,116			493,844,909			7,449	(398,435,043)	(555,188)
Ending Balance, Shares at Sep. 30, 2016				15,652	69,746,685
Exercise of stock options, Amount	271,931				$ 136			271,795
Exercise of stock options, Shares					135,730
Stock-based compensation	7,891,595							7,891,595
Common stock- Restricted Stock Units vesting, Amount	(403,261)				$ 481			(403,742)
Common stock- Restricted Stock Units vesting, Shares					481,212
Stock issuances			$ 12,420,000				$ 1,746			$ 12,418,254
Stock issuances, Shares							1,745,810
Preferred stock converted to common stock, Amount				$ (16)	$ 2,671			(2,655)
Preferred stock converted to common stock, Shares				(15,652)	2,670,989
Exercise of exchange rights, Amount	17,150				$ 5			17,145
Exercise of exchange rights, Shares					5,000
Foreign currency translation adjustments	25,783										25,783
Net loss	(34,380,295)											(34,380,295)
Ending Balance, Amount at Sep. 30, 2017	80,867,162				$ 167,155			514,037,301			33,232	(432,815,338)	(555,188)
Ending Balance, Shares at Sep. 30, 2017					74,785,426
Exercise of warrants, Amount	1,237,429				$ 288			1,237,141
Exercise of warrants, Shares					288,473
Exercise of stock options, Amount	$ 2,656,710				$ 605			2,656,105
Exercise of stock options, Shares	604,611				604,611
Stock-based compensation	$ 8,454,607							8,454,607
Common stock- Restricted Stock Units vesting, Amount	(54,668)				$ 1,327			(55,995)
Common stock- Restricted Stock Units vesting, Shares					1,326,792
Stock issuances	56,585,035				$ 11,500			56,573,535
Stock issuances, Shares					11,500,000
Foreign currency translation adjustments	(54,796)										(54,796)
Net loss	(54,450,478)											(54,450,478)
Ending Balance, Amount at Sep. 30, 2018	$ 95,241,001				$ 180,875			$ 582,902,694			$ (21,564)	$ (487,265,816)	$ (555,188)
Ending Balance, Shares at Sep. 30, 2018					88,505,302